Advancing Topical Therapies for Rare Dermatologic Diseases for Safer, More Targeted Treatment
Time: 1:30 pm
day: Day Two PM
Details:
- Enabling topical delivery of novel molecules, aiming to reduce systemic exposure and adverse events in rare skin conditions
- Understanding the different regulatory and funding approaches required for the rare space
- SGT-610, currently in Phase 3 for Gorlin Syndrome, offers an alternative to systemic hedgehog inhibitors with a potentially improved safety profile
- SGT-210, in Phase 1 for Darier disease and other rare disorders, represents a new approach to targeting keratin mutations through localized therapy
